Genedrive Regulatory News (GDR)

5 Mar 2008 16:31

EpiStem Holdings plc05 March 2008 Epistem strengthens management team with the appointment of Lydia Meyer-Turksonas Director of Biomarker Division. Epistem is pleased to announce the appointment of Lydia Meyer-Turkson asDirector of its emerging Biomarker Division. Lydia will lead the continuedexpansion of the Division managing strategic collaborations with Pharmaceuticaland Biotechnology companies using Epistem's plucked hair biomarker technology. Lydia brings more than 14 years Business Development experience of ContractResearch in drug development. Prior to joining Epistem, Lydia had been VPBusiness Development at Evotec, where she identified, structured, negotiated andclosed drug discovery collaborations in Europe key to the company's businessstrategies. Lydia has previously held senior commercial roles with US contractresearch companies including Quintiles and Covance. She holds a BSc and MPhil inChemistry from University College Cardiff and an MBA from Manchester BusinessSchool. On the commencement of her employment with Epistem, Lydia was awarded shareoptions as detailed below. The share options will vest according to the salesperformance of the Biomarker Division over the period to 30th June 2011. The share options have an exercise price of 153 pence, being the closing shareprice on 4th March 2008. Following this award, Lydia will hold the following numbers of share options: Senior Executive Share option New share options Total share option Share options held as holding prior to granted holding after % of issued capital award awardL Meyer-Turkson 0 71,918 71,918 1% For further information, please contact: Matthew Walls, CEO/John Rylands, Financial Director Epistem Holdings Plc Tel: +44 (0)161 606 7258 Thilo Hoffmann/Gareth PriceLandsbanki Securities (UK) LimitedTel: +44 (0)207 426 9000 Mike Wort / Anna DunphyDe Facto Communications LimitedTel: +44 (0)207 861 3838 This information is provided by RNS The company news service from the London Stock Exchange